The active antimicrobial system is intended for use in orthopedic reduction and internal fixation procedures. In vitro testing of the OrthoFuzIon screw showed activity against MRSA and other common pathogens. In the next few months, the company plans to launch the product in selected European markets.
“Data presented at a recent U.S. scientific meeting highlighted the fact that orthopedic surgical-site infections add an incremental $62,000 of cost to these cases. Hospital-acquired infections are becoming a significant challenge to the healthcare system. MRSA alone has been estimated to cost the U.S. healthcare system $34 billion a year and account for over 8 million additional and unnecessary hospital days. The cost burden of such infections is increasingly being shifted to hospitals, further heightening the awareness of the importance of reducing these complications,” said Paul Chirico, president and CEO of Silver Bullet Therapeutics.
More articles on devices:
Orthofix has high volume, trades low — 5 things to know
Simplify Medical gets FDA IDE for non-metal cervical disc — 5 things to know
11 key notes on K2M’s 2014 financial report — Gross profit up 15.4%
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
